Selective versus nonselective beta-blockade for heart failure therapy: are there lessons to be learned from the COMET trial?
D000319:Adrenergic beta-Antagonists / Q000008:administration & dosage / Q000627:therapeutic use*; D017298:Bisoprolol / Q000008:administration & dosage / Q000627:therapeutic use; D002227:Carbazoles / Q000008:administration & dosage / Q000627:therapeutic use; D000077261:Carvedilol; D004305:Dose-Response Relationship, Drug; D005060:Europe / Q000453:epidemiology; D006333:Heart Failure / Q000188:drug therapy* / Q000453:epidemiology / Q000209:etiology; D006801:Humans; D008790:Metoprolol / Q000008:administration & dosage / Q000627:therapeutic use; D011412:Propanolamines / Q000008:administration & dosage / Q000627:therapeutic use; D018342:Receptors, Adrenergic, beta-1 / Q000187:drug effects; D012307:Risk Factors; D013564:Sympathetic Nervous System / Q000187:drug effects; D018487:Ventricular Dysfunction, Left / Q000150:complications / Q000188:drug therapy / Q000453:epidemiology
D000319:Adrenergic beta-Antagonists; D002227:Carbazoles; D011412:Propanolamines; D018342:Receptors, Adrenergic, beta-1; D000077261:Carvedilol; D008790:Metoprolol; D017298:Bisoprolol